{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:30:36Z","timestamp":1790130636282,"version":"4.0.1"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T00:00:00Z","timestamp":1575590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02855","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T06:35:11Z","timestamp":1575614111000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?"],"prefix":"10.3389","volume":"10","author":[{"given":"Zachary S.","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,12,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitidesa","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B2","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","article-title":"ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients","volume":"12","author":"Cornec","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1002\/art.34562","article-title":"Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis","volume":"64","author":"Lionaki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/art.40034","article-title":"Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"69","author":"Merkel","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1002\/art.38036","article-title":"Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis","volume":"65","author":"Xie","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1681\/ASN.2010101058","article-title":"DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans","volume":"22","author":"Cao","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","article-title":"Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease","volume":"10","author":"Jennette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1182\/blood.V96.8.2822","article-title":"Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils","volume":"96","author":"Hess","year":"2000","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"643.e9","DOI":"10.1016\/j.amjmed.2006.08.016","article-title":"ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis","volume":"120","author":"Finkielman","year":"2007","journal-title":"Am J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S1081-1206(10)61400-7","article-title":"Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement","volume":"93","author":"Bansal","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.2215\/CJN.10411012","article-title":"Relation between asymptomatic proteinase 3 antibodies and future granulomatosis with polyangiitis","volume":"8","author":"Olson","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nm.1959","article-title":"Netting neutrophils in autoimmune small-vessel vasculitis","volume":"15","author":"Kessenbrock","year":"2009","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/art.41047","article-title":"Neutrophil extracellular trap formation is intrinsically distinct in ANCA-associated vasculitis and systemic lupus erythematosus","volume":"71","author":"van Dam","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1002\/art.41011","article-title":"Measuring circulating complement activation products in myeloperoxidase and proteinase 3 antineutrophil cytoplasmic antibody vasculitis","volume":"71","author":"Wu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B21","unstructured":"National Library of Medicine2019"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/art.40471","article-title":"Brief report: circulating cytokine profiles and antineutrophil cytoplasmic antibody specificity in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"70","author":"Berti","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.autrev.2013.06.016","article-title":"The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis","volume":"12","author":"Gomez-Puerta","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2215\/CJN.03501006","article-title":"Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study","volume":"2","author":"Hogan","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7326\/0003-4819-120-1-199401010-00003","article-title":"Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis","volume":"120","author":"Stegeman","year":"1994","journal-title":"Ann Intern Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group","volume":"335","author":"Stegeman","year":"1996","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/rheumatology\/kex001","article-title":"Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate","volume":"56","author":"Salmela","year":"2017","journal-title":"Rheumatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/1529-0131(200002)43:2<405::AID-ANR22>3.0.CO;2-5","article-title":"Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies","volume":"43","author":"Choi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/nrneph.2012.108","article-title":"Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis","volume":"8","author":"Chen","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.2215\/CJN.03440411","article-title":"Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease","volume":"6","author":"McGrath","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM198806233182504","article-title":"Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis","volume":"318","author":"Falk","year":"1988","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/ajcp\/111.4.507","article-title":"International consensus statement on testing and reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)","volume":"111","author":"Savige","year":"1999","journal-title":"Am J Clin Pathol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/annrheumdis-2016-209507","article-title":"Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays","volume":"76","author":"Damoiseaux","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/rheumatology\/kex170","article-title":"A multicentre study to improve clinical interpretation of proteinase-3 and myeloperoxidase anti-neutrophil cytoplasmic antibodies","volume":"56","author":"Bossuyt","year":"2017","journal-title":"Rheumatology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.7326\/0003-4819-147-9-200711060-00005","article-title":"Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis","volume":"147","author":"Finkielman","year":"2007","journal-title":"Ann Intern Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis\u2013a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/art.39637","article-title":"Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3","volume":"68","author":"Fussner","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/rheumatology\/ker205","article-title":"Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K","volume":"50","author":"Fujimoto","year":"2011","journal-title":"Rheumatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/art.39812","article-title":"Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-positive and ANCA-negative patients with granulomatosis with polyangiitis (Wegener's): distinct patient subsets","volume":"68","author":"Miloslavsky","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.semarthrit.2018.05.003","article-title":"Myeloperoxidase-ANCA-positive granulomatosis with polyangiitis is a distinct subset of ANCA-associated vasculitis: a retrospective analysis of 455 patients from a single center in China","volume":"48","author":"Chang","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B43","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2215\/CJN.07340713","article-title":"Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis","volume":"9","author":"Pendergraft","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3899\/jrheum.161224","article-title":"Pulmonary involvement in Antineutrophil Cytoplasmic Antibodies (ANCA)-associated vasculitis: the influence of ANCA subtype","volume":"44","author":"Mohammad","year":"2017","journal-title":"J Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1002\/art.39786","article-title":"Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener's) is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German vasculitis referral center","volume":"68","author":"Schirmer","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.semarthrit.2017.12.002","article-title":"Bronchiectasis is highly prevalent in anti-MPO ANCA-associated vasculitis and is associated with a distinct disease presentation","volume":"48","author":"Neel","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.2215\/CJN.01020113","article-title":"Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis","volume":"8","author":"de Joode","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B48","first-page":"S77","article-title":"Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts","volume":"33","author":"Pagnoux","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","article-title":"Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis","volume":"143","author":"Hogan","year":"2005","journal-title":"Ann Intern Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e6083","DOI":"10.1097\/MD.0000000000006083","article-title":"Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity","volume":"96","author":"Solans-Laque","year":"2017","journal-title":"Medicine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1002\/art.38044","article-title":"Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/art.39614","article-title":"Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease","volume":"68","author":"Rhee","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1046\/j.1523-1755.2000.00080.x","article-title":"Antiproteinase 3- and antimyeloperoxidase-associated vasculitis","volume":"57","author":"Franssen","year":"2000","journal-title":"Kidney Int"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1046\/j.1523-1755.2002.00605.x","article-title":"Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients","volume":"62","author":"Hauer","year":"2002","journal-title":"Kidney Int"},{"key":"B60","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000085854","article-title":"Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement","volume":"28","author":"Rihova","year":"2005","journal-title":"Kidney Blood Press Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3899\/jrheum.131038","article-title":"A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis","volume":"41","author":"Mohammad","year":"2014","journal-title":"J Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1136\/annrheumdis-2016-210942","article-title":"Mortality in ANCA-associated vasculitis: a meta-analysis of observational studies","volume":"76","author":"Tan","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.semarthrit.2015.07.009","article-title":"Improved survival in granulomatosis with polyangiitis: A general population-based study","volume":"45","author":"Wallace","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"B64","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/acr.22976","article-title":"Nationwide trends in hospitalizations and in-hospital mortality of granulomatosis with polyangiitis","volume":"69","author":"Wallace","year":"2017","journal-title":"Arthritis Care Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez059.048","article-title":"Cardiovascular disease is the most common cause of death in ANCA-associated vasculitis","volume":"58","author":"Wallace","year":"2019","journal-title":"Rheumatology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/acr.20433","article-title":"A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis","volume":"63","author":"Suppiah","year":"2011","journal-title":"Arthritis Care Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"28","DOI":"10.7326\/0003-4819-111-1-28","article-title":"Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis","volume":"111","author":"Nolle","year":"1989","journal-title":"Ann Intern Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","article-title":"Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"13","author":"Bossuyt","year":"2017","journal-title":"Nat Rev Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02855\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T06:35:14Z","timestamp":1575614114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02855\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":68,"alternative-id":["10.3389\/fimmu.2019.02855"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02855","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]},"article-number":"2855"}}